Currently, a phase Ib clinical trial is evaluating the efficiency of palbociclib, letrozole, and venetoclax in ER-positive and BCL-2-positive breast cancer patients (PALVEN, NCT03900884) [110]. Here, ESR1 is linked to breast cancer.